Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, ...

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, ...

Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at closing and up to 2,050,000 Oculis ordinary shares subject to lockup release over a period of up…

Oculis to Acquire Global Rights to Privosegtor from Accure Therapeutics

Key Takeaways Oculis has agreed to acquire Accure Therapeutics’ worldwide development and commercial rights to Privosegtor, terminating the companies’ existing license agreement  The broader transaction, which also includes the preclinical candidate ACT-02, provides for $3.8 million in upfront cash and up to 2.05 million Oculis ordinary shares Privosegtor is advancing in the PIONEER-1 registrational trial for optic neuritis, while Oculis plans…